scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.

 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

A multicenter, randomized, open-label, 2-arm, Phase II trial with a safety lead-in phase evaluating the combination of encorafenib and cetuximab versus irinotecan/cetuximab or infusional 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI)/cetuximab in Chinese patients with BRAFV600E mutant metastatic colorectal cancer.

Oncology Phase II Active September 02, 2021 September 2024

Study of FIH of STX-241 in locally advanced or metastatic NSCLC resistant to EGFR TKIs (STX-241FIH)

Oncology Phase I / II Active September 17, 2024 July 2030

Multicentre, multi-country, prospective, observational, post-authorisation safety study to describe the incidence of discontinuation due to diarrhoea within the first 3 months of treatment with neratinib, in adult breast cancer patients treated in extended adjuvant in a real-world setting: the NERLYFE study..

Oncology RWE Active not recruiting May 09, 2022 January 2026

Study of the combination of Binimetinib and Encorafenib in adolescent patients with unresectable or Metastatic BRAF V600-mutant Melanoma

Oncology Phase I Active not recruiting August 03, 2020 September 05, 2025

Multicenter, Open-label, Phase II Study with a Safety Lead-in part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAFV600E mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer who are BRAF- and MEK inhibitor treatment-naïve

Oncology Phase II Active not recruiting May 27, 2024 April 2026

Natural History and Disease Burden of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED): An Observational, Multicentre, International Study

Dermatology RWE Active not recruiting July 2023 September 2026

An intra-individual randomised controlled study to evaluate the efficacy and tolerance of the product RV4421 A BS0042 in association with a moderately potent topical corticosteroid in adults with atopic dermatitis

Dermatology Phase II Completed October 01, 2014 July 09, 2015

Analgesic profile of 3 new Ibuprofen lozenges (V0498TA01A 15mg, 25mg,

Central Nervous System Phase II Completed February 15, 2012 November 02, 2012

Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder

Mental Health Phase III Completed February 22, 2007 April 15, 2008

A randomised, double blind, controlled, multicentre study in infants with infantile hemangioma to compare propranolol gel to placebo

Dermatology Phase II Completed February 10, 2012 May 09, 2013

Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study

Cardiovascular Phase II Completed October 07, 2009 May 25, 2010

The effect of Minalcipran 100mg BID on sensitivity to stimulus-evoked pain in patients with Fibromyalgia : a FMRI neuroimaging study

Central Nervous System Phase II Completed October 21, 2005 April 26, 2007

Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy

Oncology Phase II Completed October 26, 2015 October 15, 2018

A randomized, single-center, open-label, single dose, two-period, crossover pivotal bioequivalence study comparing binimetinib 3 x 15 mg and 45 mg tablets in healthy participants

Oncology Phase I Completed August 31, 2022 December 2022

A retrospective non interventional study on first line treatment for patientswWith BRAF V600E mutant metastatic colorectal cancer (mCRC) (CAPSTAN CRC)

Oncology RWE Completed April 12, 2020 December 05, 2021

Efficacy of DC071 mouthwash (0.2% chlorhexidine digluconate) in peri-surgical care for preventing alveolar osteitis after third molar extraction

dental Phase IV Completed March 30, 2015 June 02, 2016

A phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant

Oncology Phase III Completed May 06, 2009 September 18, 2015

Analysis of the sensory profile of two new transdermal patches (V0116TD07AF019 and V0116TD07AF020) 21 mg/24h versus a reference transdermal patch (NICOTINELL TTS) 21 mg/24h

Dermatology Phase II Completed 2007 February 07, 2008

Assessment of the activity of a new cream containing betamethasone dipropionate at 0.010%, 0.025% and 0.050% versus reference products using a vasoconstriction assay in healthy subjects

Dermatology Phase II Completed 2008 April 16, 2009

Non inferiority study of a malathion 0.5% lotion versus reference therapy in the treatment of head lice: multicentre, randomised, investigator masked, parallel group

Parasite Phase III Completed November 24, 2008 November 02, 2009

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

SPONSOR: PFIZER

Breast cancer 

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

SPONSOR: ATARA